Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 347,793 shares, an increase of 758.6% from the May 31st total of 40,505 shares. Based on an average daily volume of 3,878,713 shares, the days-to-cover ratio is currently 0.1 days. Approximately 34.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th.

Insiders Place Their Bets

In other Clearmind Medicine news, major shareholder Financial Lp Hrt sold 22,139 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total transaction of $73,280.09. Following the sale, the insider directly owned 81,353 shares of the company’s stock, valued at approximately $269,278.43. This trade represents a 21.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 252,615 shares of company stock worth $117,933.

Clearmind Medicine Trading Down 4.4%

NASDAQ:CMND traded down $0.11 during trading hours on Friday, reaching $2.38. 38,551 shares of the company were exchanged, compared to its average volume of 4,695,129. The firm has a market cap of $2.43 million, a PE ratio of -0.02 and a beta of 0.64. Clearmind Medicine has a twelve month low of $2.10 and a twelve month high of $524.00. The stock’s 50-day moving average is $4.54 and its 200-day moving average is $13.02.

Clearmind Medicine (NASDAQ:CMND) last released its earnings results on Monday, June 15th. The company reported ($6.78) EPS for the quarter.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.